Toniv,

I agree. This is a great committee. ""This is a very significant step for the Company and we are honored to have an experienced and highly esteemed group of internationally recognized cardiologists, nephrologists, and endocrinologists to lead this important MACE reduction study," stated Mr. Donald J. McCaffrey, president and chief executive officer of Resverlogix."

"Resverlogix's Phase 3 trial BETonMACE in CVD patients with DM and low HDL is planned to commence in the fall of 2015." So in the past week or so, they've reiterated on their re-vamped website, in the Annual Information Form, and in a news release that BETonMACE will be starting in Fall 2015. Sounds like a safe BET for the Fall with all of these different forms of communication consistently saying the same thing.

RVX should update their website to list the clinical steering committee for BETonMACE. I don't know why they didnt' do this last week when they did the other updates......they had already listed the clinical steering committee in the Annual Information Form at that point!

BDAZ